Cite
HARVARD Citation
Danne, T. et al. (2021). Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2. Diabetes, obesity & metabolism. 23 (3), pp. 854-860. [Online].